MedTrace Logo

An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

NCT03229252 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2019-12-30

Study results available
· View outcomes & findings →

Summary

28-Day double-blinded efficacy and safety trial of SPX-101 Inhalation Solution in adult subjects with cystic fibrosis.

Conditions

Interventions

DRUG

Placebo Inhalation Solution

Normal Saline Inhalation Solution

DRUG

SPX-101

SPX-101 Inhalation Solution

Sponsors & Collaborators

  • Spyryx Biosciences, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2019-06-20
Completion
2019-06-20

Countries

  • Canada
  • France
  • Italy
  • Portugal
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03229252 on ClinicalTrials.gov